ViewMind’s patented Digital Biomarker software, based on AI, can identify minor alterations in oculomotor patterns and correlate them to specific pathologies, cognitive functions and related areas of the brain
After completing a non-invasive and standardized evaluation, the information is uploaded and processed in ViewMind’s cloud server and returned to the physician for proper diagnosis and monitoring of diseases.
After conclusive clinical validation, ViewMind has established a unique degree of accuracy, with a non-invasive and scalable approach that can forever change the management of dementia.
Early Onset Screening
Validated on a longitudinal study, ViewMind is able to discriminate patients with Mild Cognitive Impairment who will develop Alzheimer’s or other neuro-degenerative diseases, years before Clinical Diagnostic
ViewMind has higher Sensitivity and Specificity than Complete Neurocognitive Batteries and Complex Neuroimages. Clinical Protocols show levels of accuracy comparable with Spinal Fluid Extraction and a B- Amyloid PET in the early stages of Alzheimer’s, up to 20 years before symptoms.
Gerardo Fernandez PhD
David Orozco M.D.
Ariel Arelovich PhD
Mario Parra M.D. PhD
Together with a third-party medical grade VR headset and specific stimuli, ViewMind evaluations can give actionable information for physicians to properly diagnose and define a course of action.